Oppenheimer Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR)

Oppenheimer initiated coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a report published on Friday morning, MarketBeat.com reports. The firm issued an outperform rating and a $15.00 price objective on the biopharmaceutical company’s stock.

PRQR has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. Chardan Capital restated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. JMP Securities reiterated a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.83.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR opened at $2.42 on Friday. ProQR Therapeutics has a one year low of $1.61 and a one year high of $4.62. The firm has a market cap of $197.67 million, a P/E ratio of -7.56 and a beta of 0.30. The firm has a 50-day simple moving average of $3.23 and a 200-day simple moving average of $2.52.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its stake in ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC increased its stake in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares in the last quarter. Finally, Privium Fund Management B.V. increased its stake in ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after purchasing an additional 51,663 shares in the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).